Retrospective Cohort Study
Copyright ©The Author(s) 2022.
World J Gastrointest Oncol. Sep 15, 2022; 14(9): 1699-1710
Published online Sep 15, 2022. doi: 10.4251/wjgo.v14.i9.1699
Table 1 Characteristics of patients according to the presence and absence of tumor deposits

Tumor deposits
P value
No (89624)
Yes (14131)
Sex0.827
Female43569 (48.6%)6855 (48.5%)
Male46055 (51.4%)7276 (51.5%)
Race0.420
White70019 (78.1%)11015 (77.9%)
Black10345 (11.5%)1681 (11.9%)
Others9260 (10.3%)1435 (10.2%)
Age group, yr< 0.001a
< 455740 (6.40%)1231 (8.71%)
45-7558860 (65.7%)9387 (66.4%)
≥ 7525024 (27.9%)3513 (24.9%)
TNM-stage< 0.001a
Ι24816 (27.7%)111 (0.79%)
ΙΙ29374 (32.8%)825 (5.84%)
ΙΙΙ26627 (29.7%)7697 (54.5%)
ΙV8807 (9.83%)5498 (38.9%)
T-stage< 0.001a
T115480 (17.3%)181 (1.28%)
T214312 (16.0%)482 (3.41%)
T347654 (53.2%)7890 (55.8%)
T412178 (13.6%)5578 (39.5%)
N-stage< 0.001a
N056512 (63.1%)1247 (8.82%)
N122127 (24.7%)6582 (46.6%)
N210985 (12.3%)6302 (44.6%)
M-stage< 0.001a
M080817 (90.2%)8633 (61.1%)
M18807 (9.83%)5498 (38.9%)
Liver metastasis< 0.001a
No82821 (92.4%)10377 (73.4%)
Yes6443 (7.19%)3627 (25.7%)
Unknown360 (0.40%)127 (0.90%)
Lung metastasis< 0.001a
No87677 (97.8%)13053 (92.4%)
Yes1526 (1.70%)893 (6.32%)
Unknown421 (0.47%)185 (1.31%)
Site< 0.001a
Colon71779 (80.1%)11697 (82.8%)
Rectum16603 (18.5%)2148 (15.2%)
Unknown1242 (1.39%)286 (2.02%)
CEA< 0.001a
Normal32166 (35.9%)3543 (25.1%)
Elevated20936 (23.4%)5705 (40.4%)
Borderline279 (0.31%)48 (0.34%)
Unknown36243 (40.4%)4835 (34.2%)
Perineural invasion< 0.001a
Negative75025 (83.7%)8437 (59.7%)
Positive7301 (8.15%)4659 (33.0%)
Unknown7298 (8.14%)1035 (7.32%)
Table 2 Overall survival univariate and multivariate Cox models of baseline characteristics
Univariate Cox models
Multivariate Cox model
Events/total
HR (95%CI)
P value
Events/total
HR (95%CI)
P value
Sex0.3665
Female19008/50424Reference
Male20358/533311.01 (0.99-1.03)0.3665
Race< 0.0001a< 0.0001a
White30958/81034Reference27279/73091Reference
Black5049/120261.14 (1.11-1.17)< 0.0001a4440/108211.19 (1.16-1.23)< 0.0001a
Others3359/106950.80(0.77-0.83)<.0001a2926/95520.83(0.80-0.86)<.0001a
Age group, yr< 0.0001a< 0.0001a
< 451866/6971Reference1627/6276Reference
45-7520956/682471.17 (1.11-1.22)< 0.0001a18394/615291.49 (1.42-1.57)< 0.0001a
≥ 7516544/285372.78 (2.65-2.92)< 0.0001a14624/256594.40 (4.17-4.63)< 0.0001a
TNM-stage< 0.0001a< 0.0001a
Ι4709/24927Reference4154/22321Reference
ΙΙ9334/301991.79 (1.73-1.85)< 0.0001a8362/276880.96 (0.89-1.02)0.2060
ΙΙΙ13498/343242.46 (2.38-2.55)< 0.0001a12086/311831.32 (1.21-1.43)< 0.0001a
ΙV11825/143059.08 (8.77-9.40)< 0.0001a10043/122723.27 (2.99-3.56)< 0.0001a
T-stage< 0.0001a< 0.0001a
T12794/15661Reference2259/13476Reference
T23477/147941.35 (1.29-1.42)< 0.0001a3167/137281.18 (1.12-1.25)< 0.0001a
T321562/555442.52 (2.42-2.62)< 0.0001a19171/505291.71 (1.59-1.83)< 0.0001a
T411533/177565.80 (5.57-6.05)< 0.0001a10048/157312.83 (2.63-3.05)< 0.0001a
N-stage< 0.0001a< 0.0001a
N016014/57759Reference14081/52146Reference
N112199/287091.73 (1.69-1.78)< 0.0001a10718/258850.96 (0.91-1.02)0.1880
N211153/172873.38 (3.30-3.47)< 0.0001a9846/154331.44 (1.36-1.53)< 0.0001a
M-stage< 0.0001a
M027541/89450Reference
M111825/143055.05 (4.94-5.16)< 0.0001a
Liver metastasis< 0.0001a< 0.0001a
No30670/93198Reference27418/84728Reference
Yes8406/100704.67(4.56-4.79)< 0.0001a7227/87361.33(1.28-1.39)< 0.0001a
Lung metastasis< 0.0001a< 0.0001a
No36847/100730Reference32838/91390Reference
Yes2119/24194.62 (4.42-4.83)< 0.0001a1807/20741.32 (1.25-1.38)< 0.0001a
Site< 0.0001a
Colon32774/83476Reference
Rectum5782/187510.71 (0.69-0.73)< 0.0001a
CEA< 0.0001a
Normal9708/35709Reference
Elevated14098/266412.46 (2.40-2.53)< 0.0001a
Borderline125/3271.51 (1.26-1.80)0.0001a
Perineural invasion< 0.0001a< 0.0001a
Negative28478/83462Reference27655/81868Reference
Positive7260/119602.32 (2.26-2.38)< 0.0001a6990/115961.22 (1.19-1.26)< 0.0001a
Tumor deposits< 0.0001a< 0.0001a
No30165/89624Reference26523/80813Reference
Yes9201/141312.73 (2.67-2.80)< 0.0001a8122/126511.35 (1.31-1.38)< 0.0001a
Table 3 Sensitivity analysis for effect of tumor deposits on overall survival
Analysis
HR (95%CI)
P value
Univariable analysis2.73 (2.67-2.80)< 0.0001a
Multivariable analysis1.35 (1.31-1.38)< 0.0001a
Propensity score analysis (with inverse probability of treatment weighting)1.29 (1.19-1.39)< 0.0001a
Multiple imputation for missing data analysis1.39 (1.35-1.42)< 0.0001a
Table 4 Univariable Cox analysis in patients with and without tumor deposits

TDs (no)
TDs (yes)
RHR
P value
Events/total
HR (95%CI)
P value
Events/total
HR (95%CI)
P value
Sex0.12650.0528
Female14534/43569Reference4474/6855Reference
Male15631/460551.02 (1.00-1.04)0.12654727/72760.96 (0.92-1.00)0.0528
Race< 0.0001a< 0.0001
White23736/70019Reference7222/11015Reference
Black3904/103451.16 (1.12-1.20)< 0.0001a1145/16811.06 (1.00-1.13)0.05360.91 (0.85-0.98)0.0118a
Others2525/92600.79 (0.76-0.82)< 0.0001a834/14350.83 (0.77-0.89)< 0.0001a1.05 (0.97-1.14)0.2380
Age group, yr < 0.0001a< 0.0001a
< 451201/5740Reference665/1231Reference
45-7515238/588601.26 (1.19-1.34)< 0.0001a5718/93871.23 (1.13-1.33)< 0.0001a0.98 (0.88-1.08)0.6384
≥ 7513726/250243.37 (3.18-3.58)< 0.0001a2818/35132.34 (2.15-2.55)< 0.0001a0.69 (0.63-0.77)< 0.0001a
TNM-stage< 0.0001a< 0.0001a
Ι4683/24816Reference26/111Reference
ΙΙ8962/293741.77 (1.70-1.83)< 0.0001a372/8252.40 (1.61-3.57)< 0.0001a1.36 (0.91-2.02)0.1362
ΙΙΙ9545/266272.17 (2.09-2.24)< 0.0001a3953/76973.05 (2.08-4.49)< 0.0001a1.41 (0.96-2.07)0.0836
ΙV6975/88078.05 (7.76-8.36)< 0.0001a4850/54989.25 (6.29-13.6)< 0.0001a1.15 (0.78-1.69)0.4840
T-stage< 0.0001a< 0.0001a
T12726/15480Reference68/181Reference
T23321/143121.35 (1.29-1.42)< 0.0001a156/4820.84 (0.63-1.11)0.22460.62 (0.47-0.83)0.0012a
T317029/476542.30 (2.20-2.39)< 0.0001a4533/78901.84 (1.45-2.34)< 0.0001a0.80 (0.63-1.02)0.0602
T47089/121784.84 (4.63-5.05)< 0.0001a4444/55783.69 (2.90-4.68)< 0.0001a0.76 (0.60-0.97)0.0286a
N-stage< 0.0001a< 0.0001a
N015350/56512Reference664/1247Reference
N18434/221271.53 (1.49-1.57)< 0.0001a3765/65821.14 (1.05-1.24)0.0014a0.75 (0.68-0.81)< 0.0001a
N26381/109852.86 (2.77-2.94)< 0.0001a4772/63021.99 (1.83-2.16)< 0.0001a0.70 (0.64-0.76)< 0.0001a
M-stage< 0.0001a< 0.0001a
M023190/80817Reference4351/8633Reference
M16975/88074.90 (4.77-5.04)< 0.0001a4850/54983.13 (3.00-3.27)< 0.0001a0.64 (0.61-0.67)< 0.0001a
Site< 0.0001a< 0.0001a
Colon24983/71779Reference7791/11679Reference
Rectum4595/166030.74 (0.71-0.76)< 0.0001a1187/21480.66 (0.62-0.71)< 0.0001a0.89 (0.83-0.96)0.0030a
CEA< 0.0001a< 0.0001a
Normal7926/32166Reference1782/3543Reference
Elevated9908/209362.34 (2.27-2.41)< 0.0001a4190/57051.95 (1.84-2.06)< 0.0001a0.83 (0.78-0.89)< 0.0001a
Borderline95/2791.47 (1.20-1.80)0.0002a30/481.32 (0.92-1.89)0.13430.90 (0.59-1.36)0.6100
Perineural invasion< 0.0001a< 0.0001a
Negative23417/75025Reference5061/8437Reference
Positive3845/73012.05 (1.98-2.12)< 0.0001a3415/46591.46 (1.40-1.52)< 0.0001a0.71 (0.68-0.75)< 0.0001a
Liver metastasis< 0.0001a< 0.0001a
No24811/82821Reference5859/10377Reference
Yes5164/64434.73 (4.59-4.88)< 0.0001a3242/36272.66 (2.54-2.78)< 0.0001a0.56 (0.53-0.59)< 0.0001a
Lung metastasis< 0.0001a< 0.0001a
No28622/87677Reference8225/13053Reference
Yes1297/15264.97 (4.70-5.25)< 0.0001a822/8932.40 (2.23-2.58)< 0.0001a0.48 (0.44-0.53)< 0.0001a
Table 5 N1 colorectal cancers after being restaged
Initial N stage
Restaged N1
Restaged N2
Total
N1a/b1807775218820
N1c10031331136
Total1908088519965